The Bell2Bell (B2B) Podcast

“Reunion Gold is a gold exploration company. Our activities are mainly focused around the Guiana Shield, which includes countries like French Guiana, Suriname and Guyana,” said Rick Howes, President & CEO of Reunion Gold Corp. (TSX.V: RGD) (OTCQX: RGDFF). “We’ve been well established in [Guyana], and the team that’s leading the company today includes individuals who have been based in the Guiana Shield for over 40 years now… It’s a relatively underdeveloped, underexplored region, and it has high prospectivity, as it forms the basis of a large greenstone belt, which is a very common [source] for gold deposits.”

“Reunion Gold is a gold exploration company. Our activities are mainly focused around the Guiana Shield, which includes countries like French Guiana, Suriname and Guyana,” said Rick Howes, President & CEO of Reunion Gold Corp. (TSX.V: RGD) (OTCQX: RGDFF). “We’ve been well established in [Guyana], and the team that’s leading the company today includes individuals who have been based in the Guiana Shield for over 40 years now… It’s a relatively underdeveloped, underexplored region, and it has high prospectivity, as it forms the basis of a large greenstone belt, which is a very common [source] for gold deposits.”

Bell2Bell’s latest podcast features Tyrone Docherty, President & CEO of First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF), a company committed to exploring for and providing essential and critical metals, including tellurium, gold, silver, copper and tungsten, for North American markets. 

To begin the interview, Docherty provided an introduction to the company’s business model and operating markets. 

“First Tellurium has a wonderful, high-grade gold and silver property in Canada, but it comes with this unique mineral, Tellurium, which is listed by both the United States and Canadian governments as critical,” said Docherty. “Tellurium has come into the fore over the last couple of decades, because it is used in solar panels by U.S. corporation First Solar, which uses a mixture of cadmium and tellurium, as opposed to different solar panels coming out of China. Tellurium is very important there, and it’s a very rare metal.” 

Bell2Bell’s latest podcast features Tyrone Docherty, President & CEO of First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF), a company committed to exploring for and providing essential and critical metals, including tellurium, gold, silver, copper and tungsten, for North American markets. 

To begin the interview, Docherty provided an introduction to the company’s business model and operating markets. 

“First Tellurium has a wonderful, high-grade gold and silver property in Canada, but it comes with this unique mineral, Tellurium, which is listed by both the United States and Canadian governments as critical,” said Docherty. “Tellurium has come into the fore over the last couple of decades, because it is used in solar panels by U.S. corporation First Solar, which uses a mixture of cadmium and tellurium, as opposed to different solar panels coming out of China. Tellurium is very important there, and it’s a very rare metal.” 

Bell2Bell’s latest podcast features Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV). BiondVax’s pipeline is based on an innovative platform technology of alpaca-derived nanosized antibodies, known as Nanobodies or NanoAbs, addressing infectious and autoimmune diseases with large unmet medical needs such as COVID-19, psoriasis, psoriatic arthritis, asthma and macular degeneration.

This appearance follows a December 2022 interview between Reichman and host Stuart Smith. To review the first part of the series, visit The Stock2Me Podcast.

To begin the latest interview, Reichman discussed the company’s recent achievements, as detailed in a letter to shareholders issued late last year.

“At the end of 2022, we did a round of financing and raised about $8 million. We also started the negotiations to in-license the next antibody from the Max Planck Institute – namely the antibody for targeting interleukin-17 (IL-17) for the treatment of psoriasis,” Reichman said. “We have now in-licensed the IL-17 nanobody. This is a highly promising drug.”

“If we look at the market, psoriatic patients today have several options for treatment. For example, plaque psoriasis patients have creams and other topical drugs, biologics and oral drugs… The topicals are not highly sophisticated drugs to say the least, and they come with a considerable profile of side effects. When a person needs to take steroids once in a while for an infection, they can tolerate it, but when you need to take steroids for an autoimmune disease with chronic inflammation, you create tolerance and deal with potential side effects… The biologics are highly potent, but they are restricted to moderate and severe cases of psoriasis; this accounts for only 15% of patients with psoriasis. The 85% that are left have to choose between drugs based on 1960s and 1970s technology. There hasn’t been much breakthrough in recent years to serve these patients.”

Bell2Bell’s latest podcast features Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV). BiondVax’s pipeline is based on an innovative platform technology of alpaca-derived nanosized antibodies, known as Nanobodies or NanoAbs, addressing infectious and autoimmune diseases with large unmet medical needs such as COVID-19, psoriasis, psoriatic arthritis, asthma and macular degeneration.

This appearance follows a December 2022 interview between Reichman and host Stuart Smith. To review the first part of the series, visit The Stock2Me Podcast.

To begin the latest interview, Reichman discussed the company’s recent achievements, as detailed in a letter to shareholders issued late last year.

“At the end of 2022, we did a round of financing and raised about $8 million. We also started the negotiations to in-license the next antibody from the Max Planck Institute – namely the antibody for targeting interleukin-17 (IL-17) for the treatment of psoriasis,” Reichman said. “We have now in-licensed the IL-17 nanobody. This is a highly promising drug.”

“If we look at the market, psoriatic patients today have several options for treatment. For example, plaque psoriasis patients have creams and other topical drugs, biologics and oral drugs… The topicals are not highly sophisticated drugs to say the least, and they come with a considerable profile of side effects. When a person needs to take steroids once in a while for an infection, they can tolerate it, but when you need to take steroids for an autoimmune disease with chronic inflammation, you create tolerance and deal with potential side effects… The biologics are highly potent, but they are restricted to moderate and severe cases of psoriasis; this accounts for only 15% of patients with psoriasis. The 85% that are left have to choose between drugs based on 1960s and 1970s technology. There hasn’t been much breakthrough in recent years to serve these patients.”

Bell2Bell’s latest podcast features Chairman, President and CEO Rodney Varner and CFO Ryan Confer of Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients living with cancer and diabetes. 

In this interview, Varner and Confer discuss the journeys that led them to Genprex and the incredible promise of the company’s clinical drug development pipeline. 

“This work has become a real passion for me. We have the opportunity to do real good here at Genprex on a major scale – helping millions of people around the world with serious diseases through our novel gene therapies,” said Varner. 

Confer then provided some background on what led him to join Genprex in its early days and remain with the company for well over a decade. 

“As I learned more and more about the technology, it became a passion of mine, as well,” said Confer. “What we’re trying to do in cancer – using a lipid-based delivery vehicle and working with tumor suppressor genes that are naturally occurring in the body – represents a treatment paradigm that is unique and different than other options in the space, particularly chemotherapy that has such negative side effects. It is something that we believe really has the potential to change people’s lives as they’re going through such a terrible prognosis. I was excited then, and here we are 12 years later, being able to see it coming through clinical trials, seeing how safe the program has been and seeing the impact that we’re having.” 

Bell2Bell’s latest podcast features Chairman, President and CEO Rodney Varner and CFO Ryan Confer of Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients living with cancer and diabetes. 

In this interview, Varner and Confer discuss the journeys that led them to Genprex and the incredible promise of the company’s clinical drug development pipeline. 

“This work has become a real passion for me. We have the opportunity to do real good here at Genprex on a major scale – helping millions of people around the world with serious diseases through our novel gene therapies,” said Varner. 

Confer then provided some background on what led him to join Genprex in its early days and remain with the company for well over a decade. 

“As I learned more and more about the technology, it became a passion of mine, as well,” said Confer. “What we’re trying to do in cancer – using a lipid-based delivery vehicle and working with tumor suppressor genes that are naturally occurring in the body – represents a treatment paradigm that is unique and different than other options in the space, particularly chemotherapy that has such negative side effects. It is something that we believe really has the potential to change people’s lives as they’re going through such a terrible prognosis. I was excited then, and here we are 12 years later, being able to see it coming through clinical trials, seeing how safe the program has been and seeing the impact that we’re having.” 

Bell2Bell’s latest podcast features Dr. Mark Berger, Chief Medical Officer of Genprex Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients living with cancer and diabetes.

This episode was recorded live at the venue hosting the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, the largest clinical oncology meeting of the year. Last year, there were 30,000 attendees at the meeting and another 12,000 tuning in electronically. This year’s event is estimated to be the same in size. 

Dr. Berger explained why this year has been such a great one for Genprex. To hear an exciting summary of the company’s recent accomplishments and his expectations for the future, tune into this episode. 

Bell2Bell’s latest podcast features Dr. Mark Berger, Chief Medical Officer of Genprex Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients living with cancer and diabetes.

This episode was recorded live at the venue hosting the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, the largest clinical oncology meeting of the year. Last year, there were 30,000 attendees at the meeting and another 12,000 tuning in electronically. This year’s event is estimated to be the same in size. 

Dr. Berger explained why this year has been such a great one for Genprex. To hear an exciting summary of the company’s recent accomplishments and his expectations for the future, tune into this episode.